DOI: http://dx.doi.org/10.18203/2349-2902.isj20210936

Therapeutic efficacy and safety of mesenchymal stem cells transplantation for patients with liver failure: a systematic review and meta-analysis

Feng Qi, Zongze Jiang, Jianping Gong, Yi Feng

Abstract


The aim was to pool the present clinical studies to assess the therapeutic efficacy and safety of mesenchymal stem cell transplantation (MSCT) compared with traditional supportive treatment (TST) for patients with liver failure. Publications were searched to identify relevant clinical trials in which LF patients accepted mesenchymal stem cell transplantation from the online databases of PUBMED, EMBASE, and Cochrane Library up to June 2020. Then, the short-term outcomes of 6 months, including models of end-stage liver disease (MELD) score, total bilirubin (TBIL), albumin (ALB), prothrombin activity (PTA), alanine aminotransferase (ALT), prothrombin time (PT) and cumulative survival rate were enrolled in a meta-analysis. In total, 446 patients, reported on 2 randomized controlled trials (RCTs) and 4 non-randomized trials, were included. Compared with TST, MSCT was associated with a faster decline of MELD score at 2-, 4-, 12- and 24-week, greater improvement of ALT levels at1-, 4-, 24-week, significant increase of ALB levels at 4-,12-week and remarkable raise of PTA levels at 12-, 24-week, while PT levels changed greatly at 4-week and TBIL levels observably decreased at 4-week. The cumulative survival rate of MSCT was shown significant difference at 12-week. There were no serious complications and HCC occurred after MSCT. This study suggests MSCT may be a more effective and safe strategy than TST to improve liver function parameters and alleviate liver damage in LF patients during the short-term duration of 6 months. However, more multi-center, large-scale RCTs are needed.


Keywords


Mesenchymal stem cells, MSCs, Liver failure

Full Text:

PDF

References


Failure L, Artificial Liver Group CSoID, Chinese Medical Association. [Diagnostic and treatment guidelines for liver failure (2012 version)]. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. 2013;21(3):177.

William M, Lee M, Larson AM, Stravitz RT. AASLD position paper: The management of acute liver failure: Update. Hepatology. 2011;55.

Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatology International. 2014;8(4):453-71.

Blachier M, Leleu H, Peckradosavljevic M, Valla DC, Roudotthoraval F. The burden of liver disease in Europe: a review of available epidemiological data. Journal of Hepatology. 2013;58(3):593-608.

Millis JM, Cronin DC, Johnson R, Conjeevaram H, Conlin C, Trevino S, et al. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation. 2002;74(12):1735.

AA D, Jr BR, RW B, J F, BM M, P R, et al. Prospective, Randomized, Multicenter, Controlled Trial of a Bioartificial Liver in Treating Acute Liver Failure. Annals of surgery. 2004;239(5):667-70.

Steadman RH, Van RA, Kramer DJ. Transplantation for acute liver failure: perioperative management. Current opinion in organ transplantation. 2010;15(3):368-73.

Mochida S. Indication criteria for liver transplantation for acute liver failure in Japan. Hepatology Research the Official Journal of the Japan Society of Hepatology. 2010;38(s1):S52-S5.

Wu J, Zheng SS. Liver transplantation in China: problems and their solutions. Hepatobiliary & Pancreatic Diseases International. 2004;3(2):170-4.

Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, et al. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation. Liver Transplantation. 2013;19(8):896-906.

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage Potential of Adult Human Mesenchymal Stem Cells. Science. 1994;284(5411):143-7.

L dSM, PC C, NB N. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. Journal of Cell Science. 2006;119(11):2204-13.

Eom YW, Kim G, Baik SK. Mesenchymal stem cell therapy for cirrhosis: Present and future perspectives. World J Gastroenterology. 2015;21(36):10253-61.

Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Molecular Cellular Cardiology. 2011;50(2):280-9.

Honczarenko M, Yi L, Swierkowski M, Ghiran I, Glodek AM, Leslie ESMD. Human Bone Marrow Stromal Cells Express a Distinct Set of Biologically Functional Chemokine Receptors. Stem cells (Dayton, Ohio). 2010;24(4):1030-41.

Parekkadan B, Poll DV, Megeed Z, Kobayashi N, Tilles AW, Berthiaume F, et al. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochemical Biophysical Res Communications. 2007;363(2):247-52.

Zhang Z, Wang FS. Stem cell therapies for liver failure and cirrhosis. J Hepatology. 2013;59(1):183-5.

Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurology. 2012;11(2):150-6.

Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Frontiers of Medicine. 2011;5(1):94.

Makkar RR, Smith RR, Cheng K, Malliaras K, Thomson LE, Berman D, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379(9819):895-904.

Popp FC, Fillenberg B, Eggenhofer E, Renner P, Dillmann J, Benseler V, et al. Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation a phase I study (MISOT-I). Journal of Translational Medicine,9,1(2011-07-28). 2011;9(1):124.

Suk KT, Yoon JH, Kim MY, Kim CW, Kim JK, Park H, et al. Transplantation with Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Alcoholic Cirrhosis: Phase 2 Trial. Hepatology. 2016;64(6):2185.

Hozo S, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. Bmc Medical Research Methodology. 2005;5(1):13.

Amer MEM, El-Sayed SZ, El-Kheir WA, Gabr H, Gomaa AA, El-Noomani N, et al. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. European J Gastroenterology and Hepatology. 2011;23(10):936-41.

Peng L, Xie DY, Lin BL, Liu J, Zhu HP, Xie C, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011;54(3):820-8.

Shi M, Zhang Z, Xu R, Lin H, Fu J, Zou Z, et al. Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem cells translational medicine. 2012;1(10):725-31.

Li YH, Xu Y, Wu HM, Yang J, Yang LH, Yue-Meng W. Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation in Hepatitis B Virus Related Acute-on-Chronic Liver Failure Treated with Plasma Exchange and Entecavir: a 24-Month Prospective Study. Stem cell reviews. 2016;12(6):645-53.

Lin BL, Chen JF, Qiu WH, Wang KW, Xie DY, Chen XY, et al. Allogeneic bone marrow–derived mesenchymal stromal cells for hepatitis B virus–related acute-on-chronic liver failure: A randomized controlled trial. Hepatology. 2017;66(1):209-19.

Zhang S, Liu LP, Ma WB, Jia B, Wang HF, Xie CJ. Therapeutic effect of human umbilical cord mesenchymal stem cells transplantation in the treatment of chronic liver failure. Chinese Journal of Tissue Engineering Research. 2017;21(13):2056-61.

Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003;52(6):879-85.

Xue R, Meng Q, Dong J, Li J, Yao Q, Zhu Y, et al. Clinical performance of stem cell therapy in patients with acute-on-chronic liver failure: a systematic review and meta-analysis. J Translational Medicine. 2018;16(1):126.

Larsen FS, Schmidt LE, Bernsmeier C, Rasmussen A, Isoniemi H, Patel VC, et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatology. 2016;64(1):69-78.

Sutton AJ, Song F, Gilbody SM, Abrams KR. Modelling publication bias in meta-analysis: a review. Statistical Methods in Medical Research. 2000;9(5):421.

Zhu C, Wang K, Li Y, Zhang Y, Li W, Lin W, et al. Over-expression of c-Met in bone marrow mesenchymal stem cells improves their effectiveness in homing and repair of acute liver failure. Hepatology. 2017;66:18A-9A.

Shi M, Li Y, Xu R, Meng F, Wang F. Human mesenchymal stem cell therapy increased the survival of the patients with decompensated liver cirrhosis. Hepatology International. 2017;11(1):S895.

Mohamadnejad M, Alimoghaddam K, Bagheri M, Ashrafi M, Abdollahzadeh L, Akhlaghpoor S, et al. Randomized placebo-controlled trial of mesenchymal stem cell transplantation in decompensated cirrhosis. Liver International: official journal of the International Association for the Study of the Liver. 2013;33(10):1490-6.

Liu T, Hong MU, Shen Z, Song Z, Chen X, Wang Y. Autologous adipose tissue-derived mesenchymal stem cells are involved in rat liver regeneration following repeat partial hepatectomy. Molecular Med Reports. 2016;13(3):2053-9.

Van PD, Parekkadan B, Cho CH, Berthiaume F, Nahmias Y, Tilles AW, et al. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology. 2010;47(5):1634-43.